
AZD1222 claims 79% effecacy in pivotal US study
For exactly one day, the belief that AstraZeneca's COVID-19 vaccine AZD1222 may be better than its reputation lasted. But because the ailing vaccine...

Abingworth raises US-$465m for new life sciences fund
UK-US venture capitalist Abingworth yesterday announced the final closing of its 13th life sciences venture fund, ABV 8, at US$465m exceeding...

COVID-19: Study finds neutralising antibodies to disappear rapidly
According to the “Rhineland population-based Study”, published by researchers under Prof. Monique Breteler at the DZNE in Bonn, Germany blood...

Two companies aim for 2nd-gen COVID vaccines
As scientific papers provide hints that mutants of SARS-CoV-2 that carry the N501Y and E484K mutations are able to reproduce more rapidly as the...

Oxular Ltd raises US$37m
Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

Italian Enthera Pharma raise €35m in Series A extension
Roche Venture Fund joined seed investor Sofinnova Partners and AbbVie Ventures and co-investors including the JDRF T1D Fund, an investor group...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...